Scalper1 News
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker’s biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG) deeper into the growing field of rare-disease drugs, helping it diversify from its core business in attention-deficit treatments. It has also made a number of smaller buyouts. This year, Shire’s Scalper1 News
Scalper1 News